Search the Newsreel

Larimar Therapeutics (LRMR) to Announce Earnings on Thursday

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Analysts

Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp

Larimar Therapeutics (LRMR) faces significant regulatory and manufacturing risks for its nomlabofusp drug, impacting its accelerated approval path. Delays in BLA submission or issues with third-party manufacturers, especially those with FDA Form 483 observations, could postpone commercialization and affect investor confidence. Despite these challenges, …

Wedbush Cuts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $11.00

Larimar: Q2 Earnings Snapshot

Larimar Therapeutics, Inc. (LRMR) reported a second-quarter loss of $32.8 million, or 30 cents per share. This performance exceeded Wall Street expectations, as analysts surveyed by Zacks Investment Research had estimated a loss of 39 cents per share. The report was generated by Automated …

Larimar Therapeutics (LRMR) Gains 3.27% as Biotech Stock Approaches Key $4.32 Resistance - Post-Earnings Moves

Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary

Larimar Therapeutics reported a net loss of $32.8 million and diluted EPS of $(0.30) for the second quarter of 2026. This represents a widening of net loss compared to the previous year, though the EPS loss improved. The company highlighted significant progress including FDA …

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics announced its second-quarter 2026 financial and business update, highlighting significant progress in the development of nomlabofusp for Friedreich’s ataxia. Key achievements include positive longer-term open-label study data demonstrating sustained increases in frataxin levels and clinical improvements, initiation of a rolling BLA submission …

SummitTX Capital L.P. Invests $1.71 Million in Larimar Therapeutics, Inc. $LRMR

SummitTX Capital L.P. has acquired a new stake of 379,765 shares in Larimar Therapeutics, Inc. (NASDAQ:LRMR) valued at approximately $1.71 million. This investment comes as other institutional investors have also adjusted their holdings in the company, which has 91.92% institutional ownership. Analyst sentiment for …

ETFs Investing in Larimar Therapeutics, Inc. Stocks

This article lists various ETFs that currently hold stocks of Larimar Therapeutics, Inc. The ETFs are sorted by their market value and include details such as weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. …

Larimar Therapeutics Inc (LRMR) Institutional Confidence

Larimar Therapeutics Inc (LRMR) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 79.20%, a 23.65% decrease quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.34M shares.

Larimar Therapeutics Inc (LRMR) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of Larimar Therapeutics Inc (LRMR), noting its weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. The company's financial score is 5.45, ranking it 359 out of 386 in its sector. Several …

Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Larimar Therapeutics Inc's (LRMR) shareholder structure. It lists major shareholders such as Deerfield Management Company and Blue Owl Capital Holdings, categorizes shareholders by type (e.g., Hedge Fund, Investment Advisor), and presents institutional shareholding data over several quarters. …

Larimar Therapeutics Inc (LRMR) Cash Flow

This article provides a detailed historical cash flow statement for Larimar Therapeutics Inc (LRMR), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes, offering investors a comprehensive view of the company's financial health and …

Enterprise value to EBITDA forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR

This article focuses on the enterprise value to EBITDA forward metric for Larimar Therapeutics, Inc. (NASDAQ: LRMR). It appears to be a financial data presentation rather than an analytical piece, stemming from TradingView. The content provided is minimal, primarily listing the company name and …

TradingKey

This article provides a detailed quarterly and annual income statement for Larimar Therapeutics Inc (LRMR) from FY2012Q4 through FY2026Q1, including metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income. It highlights the company's continuous negative net income and operating …

Larimar Therapeutics Market Sentiment

This article analyzes market sentiment for Larimar Therapeutics (LRMR) based on analyst consensus, short interest, options flow, and insider activity. Key signals indicate a "Buy" consensus from analysts with a high average price target, significant insider buying, but also a notable bearish short interest. …

Larimar Therapeutics, Inc. Revenue Breakdown – NASDAQ:LRMR

This article provides details on Larimar Therapeutics, Inc. (NASDAQ: LRMR) including its stock market information, financial overviews, and access to documents and news. It indicates that the market is closed without any trades and offers various fundamental and statistical data points like statements, statistics, …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) following two significant stock price drops. The investigation focuses on whether the company misled investors regarding the safety of its Friedreich's Ataxia treatment, nomlabofusp, after reports of anaphylaxis were disclosed …

LRMR|Larimar Therapeutics Inc|Price:4.050|Chg%:+0.040

Larimar Therapeutics Inc (LRMR) is a clinical-stage biotechnology company focusing on treatments for rare diseases, with its lead candidate nomlabofusp targeting Friedreich's ataxia. Despite relatively weak fundamentals and technicals, the company has high growth potential and is considered fairly valued, ranking 135 out of …

LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25

LifeSci Capital has reiterated its Buy rating on Larimar Therapeutics (LRMR.US), maintaining its target price at $25. This indicates continued confidence in the company's prospects by the investment firm.

Price to earnings forward of Larimar Therapeutics, Inc. – SWB:ZA71

This article provides financial information for Larimar Therapeutics, Inc. (SWB:ZA71), specifically focusing on its price-to-earnings forward metric. The content highlights the stock's status on the Stuttgart Stock Exchange, indicating it was closed with no trades, and is structured around data from TradingView. It appears …

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (LRMR) has submitted the initial module of its Biologics License Application (BLA) to the U.S. FDA for accelerated approval of its Nomlabofusp therapy, targeting Friedreich's ataxia. The therapy showed positive results in an open-label study, and the FDA confirmed that existing data …